Current approaches and future directions in the treatment of HER2-positive breast cancer

Cancer Treatment Reviews

Volumn 39, Issue 3, 2013, Pages 219-229

  Hurvitz, Sara A ^a   Hu, Yufang ^a   O'Brien, Neil ^a   Finn, Richard S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; HER2; Lapatinib; Resistance; Trastuzumab; Tyrosine kinase inhibitors

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ADERBASIB; AFATINIB; ALVESPIMYCIN; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ERTUMAXOMAB; EVEROLIMUS; GEFITINIB; LAPATINIB; LONAFARNIB; NAVELBINE; NERATINIB; NEUVACCINE; PACLITAXEL; PAZOPANIB; PERTUZUMAB; PLACEBO; RAPAMYCIN; RIDAFOROLIMUS; SUNITINIB; TANESPIMYCIN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL FATE; CELL SURVIVAL; DIMERIZATION; DNA DAMAGE; DNA REPAIR; DRUG CONJUGATION; DRUG POTENTIATION; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; GENE OVEREXPRESSION; HER2 POSITIVE BREAST CANCER; HUMAN; HYPERTENSION; METASTASIS; NONHUMAN; OVERALL SURVIVAL; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2;

EID: 84873993908     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.04.008     Document Type: Review

References (114)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
3. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98(19):10869-10874.
4. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
5. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244(4905):707-712.
6. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2):127-137.
7. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
8. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684.
9. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26):2733-2743.
10. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20(3):719-726.
11. Valabrega G., Montemurro F., Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007, 18(6):977-984.
12. Bender L.M., Nahta R. Her2 cross talk and therapeutic resistance in breast cancer. Front Biosci 2008, 13:3906-3912.
13. Wong K.K., Engelman J.A., Cantley L.C. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010, 20(1):87-90.
14. Albanell J., Dalmases A., Rovira A., Rojo F. MTOR signalling in human cancer. Clin Transl Oncol 2007, 9(8):484-493.
15. Zhou X., Tan M., Stone Hawthorne V., Klos K.S., Lan K.H., Yang Y., et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004, 10(20):6779-6788.
16. Rojo F., Najera L., Lirola J., Jimenez J., Guzman M., Sabadell M.D., et al. Ramon y Cajal S: 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007, 13(1):81-89.
17. Bedard P.L., de Azambuja E., Cardoso F. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets 2009, 9(2):148-162.
18. Siddiqa A., Long L.M., Li L., Marciniak R.A., Kazhdan I. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer 2008, 8:129.
19. Nahta R., Yuan L.X., Zhang B., Kobayashi R., Esteva F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005, 65(23):11118-11128.
20. Blackwell K.L., Dewhirst M.W., Liotcheva V., Snyder S., Broadwater G., Bentley R., et al. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res 2004, 10(12 Pt 1):4083-4088.
21. Konecny G.E., Meng Y.G., Untch M., Wang H.J., Bauerfeind I., Epstein M., et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004, 10(5):1706-1716.
22. Le X.F., Pruefer F., Bast R.C. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 2005, 4(1):87-95.
23. Pietras R.J., Fendly B.M., Chazin V.R., Pegram M.D., Howell S.B., Slamon D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994, 9(7):1829-1838.
24. Pietras R.J., Pegram M.D., Finn R.S., Maneval D.A., Slamon D.J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998, 17(17):2235-2249.
25. Pietras R.J., Poen J.C., Gallardo D., Wongvipat P.N., Lee H.J., Slamon D.J. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999, 59(6):1347-1355.
26. Pohlmann P.R., Mayer I.A., Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009, 15(24):7479-7491.
27. Kruser T.J., Wheeler D.L. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 2010, 316(7):1083-1100.
28. Izumi Y., Xu L., di Tomaso E., Fukumura D., Jain R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416(6878):279-280.
29. Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27(34):5838-5847.
30. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6(4):443-446.
31. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26(11):1789-1796.
32. Tamura K.S.C., Koizumi F., Kouno T., Katsumata N., Kinoshita T., Aogi K., et al. Correlation of FcγR IIa-H131R and IIIa-V158F polymorphisms and clinical outcome of trastuzumab in both neoadjuvant and metastatic setting in patients with HER-2 positive breast cancer. J Clin Oncol 2009, 27(15):1100.
33. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, et al. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 2012. [Epub ahead of print].
34. Konecny G.E., Pegram M.D., Venkatesan N., Finn R., Yang G., Rahmeh M., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66(3):1630-1639.
35. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28(7):1124-1130.
36. Depowski P.L., Rosenthal S.I., Ross J.S. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001, 14(7):672-676.
37. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6(2):117-127.
38. Faratian D., Goltsov A., Lebedeva G., Sorokin A., Moodie S., Mullen P., et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res 2009, 69(16):6713-6720.
39. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12(4):395-402.
40. Esteva F.J., Guo H., Zhang S., Santa-Maria C., Stone S., Lanchbury J.S., et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010, 177(4):1647-1656.
41. Johnston S., Trudeau M., Kaufman B., Boussen H., Blackwell K., LoRusso P., et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008, 26(7):1066-1072.
42. Xia W., Husain I., Liu L., Bacus S., Saini S., Spohn J., et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 2007, 67(3):1170-1175.
43. O'Brien N.A., Browne B.C., Chow L., Wang Y., Ginther C., Arboleda J., et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010, 9(6):1489-1502.
44. Eichhorn P.J., Gili M., Scaltriti M., Serra V., Guzman M., Nijkamp W., et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008, 68(22):9221-9230.
45. Gardner H., Nuciforo P., Liu W-H., Lee B., Rheinhardt J., Barrett C., et al. PI3 kinase pathway analysis in tissue microarrays using laser capture microdissection and immunohistochemistry. Cancer Res 2009, 69(24s). Abstract 4043.
46. Dupont J., Laenkholm A.V., Knoop A., Ewertz M., Barrett C.J., Hackl W., et al. PIK3CA mutations can be acquired during tumor progression in breast cancer. Cancer Res 2009, 69(24s). [Abstract 6023].
47. Kataoka Y., Mukohara T., Shimada H., Saijo N., Hirai M., Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2010, 21(2):255-262.
48. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008, 68(14):5878-5887.
49. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 2003, 100(15):8933-8938.
50. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15(5):429-440.
51. Ritter C.A., Perez-Torres M., Rinehart C., Guix M., Dugger T., Engelman J.A., et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007, 13(16):4909-4919.
52. Valabrega G., Montemurro F., Sarotto I., Petrelli A., Rubini P., Tacchetti C., et al. TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene 2005, 24(18):3002-3010.
53. Serra V., Scaltriti M., Prudkin L., Eichhorn P.J., Ibrahim Y.H., Chandarlapaty S., et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011, 30(22):2547-2557.
54. Gijsen M., King P., Perera T., Parker P.J., Harris A.L., Larijani B., et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol 2010, 8(12):e1000563.
55. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445(7126):437-441.
56. Zhang S., Huang W.C., Li P., Guo H., Poh S.B., Brady S.W., et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011, 17(4):461-469.
57. Rexer B.N., Ham A.J., Rinehart C., Hill S., de Matos Granja-Ingram N., Gonzalez-Angulo A.M., et al. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011, 30(40):4163-4174.
58. Saez R., Molina M.A., Ramsey E.E., Rojo F., Keenan E.J., Albanell J., et al. P95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006, 12(2):424-431.
59. Scaltriti M., Rojo F., Ocana A., Anido J., Guzman M., Cortes J., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007, 99(8):628-638.
60. Kostler W.J., Schwab B., Singer C.F., Neumann R., Rucklinger E., Brodowicz T., et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 2004, 10(5):1618-1624.
61. Lennon S., Barton C., Banken L., Gianni L., Marty M., Baselga J., et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 2009, 27(10):1685-1693.
62. Finn R.S., Gagnon R., Di Leo A., Press M.F., Arbushites M., Koehler M. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol 2009, 27(33):5552-5558.
63. Walker-Daniels J., Hess A.R., Hendrix M.J., Kinch M.S. Differential regulation of EphA2 in normal and malignant cells. Am J Pathol 2003, 162(4):1037-1042.
64. Zhuang G., Brantley-Sieders D.M., Vaught D., Yu J., Xie L., Wells S., et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 2010, 70(1):299-308.
65. Lu Y., Zi X., Zhao Y., Mascarenhas D., Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93(24):1852-1857.
66. Harris L.N., You F., Schnitt S.J., Witkiewicz A., Lu X., Sgroi D., et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007, 13(4):1198-1207.
67. Nagy P., Friedlander E., Tanner M., Kapanen A.I., Carraway K.L., Isola J., et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005, 65(2):473-482.
68. Nahta R., Takahashi T., Ueno N.T., Hung M.C., Esteva F.J. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004, 64(11):3981-3986.
69. Vazquez-Martin A., Oliveras-Ferraros C., Menendez J.A. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One 2009, 4(7):e6251.
70. Liu L., Greger J., Shi H., Liu Y., Greshock J., Annan R., et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009, 69(17):6871-6878.
71. Xia W., Bacus S., Hegde P., Husain I., Strum J., Liu L., et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 2006, 103(20):7795-7800.
72. von Minckwitz G., du Bois A., Schmidt M., Maass N., Cufer T., de Jongh F.E., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009, 27(12):1999-2006.
73. Blackwell K., Burstein H.J., Sledge G.W., Stein S., Ellis C., Casey M., et al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Cancer Res 2009, 69(24 Suppl.). [Abstract 61].
74. Baselga J., Bradbury I., Eidtmann H., Di Cosimo S., de Azambuja E., Aura C., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379(9816):633-640.
75. Mosley J.D., Poirier J.T., Seachrist D.D., Landis M.D., Keri R.A. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Mol Cancer Ther 2007, 6(8):2188-2197.
76. Perez E.A., Romond E.H., Suman V.J., Jeong J.H., Davidson N.E., Geyer C.E., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011, 29(25):3366-3373.
77. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365(14):1273-1283.
78. Untch M., Gelber R.D., Jackisch C., Procter M., Baselga J., Bell R., et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008, 19(6):1090-1096.
79. Brufsky A., Lembersky B., Schiffman K., Lieberman G., Paton V.E. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 2005, 6(3):247-252.
80. Dowsett M., Allred C., Knox J., Quinn E., Salter J., Wale C., et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008, 26(7):1059-1065.
81. De Laurentiis M., Arpino G., Massarelli E., Ruggiero A., Carlomagno C., Ciardiello F., et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005, 11(13):4741-4748.
82. Lipton A., Ali S.M., Leitzel K., Demers L., Chinchilli V., Engle L., et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002, 20(6):1467-1472.
83. Osborne C.K., Shou J., Massarweh S., Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005, 11(2 Pt. 2):865s-870s.
84. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96(12):926-935.
85. Witters L., Engle L., Lipton A. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncol Rep 2002, 9(6):1163-1166.
86. Kaufman B., Mackey J.R., Clemens M.R., Bapsy P.P., Vaid A., Wardley A., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27(33):5529-5537.
87. Johnston S., Pippen J., Pivot X., Lichinitser M., Sadeghi S., Dieras V., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27(33):5538-5546.
88. Schwartzberg L.S., Franco S.X., Florance A., O'Rourke L., Maltzman J., Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010, 15(2):122-129.
89. Miller T.W., Forbes J.T., Shah C., Wyatt S.K., Manning H.C., Olivares M.G., et al. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 2009, 15(23):7266-7276.
90. Lu C.H., Wyszomierski S.L., Tseng L.M., Sun M.H., Lan K.H., Neal C.L., et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007, 13(19):5883-5888.
91. Andre F., Campone M., O'Regan R., Manlius C., Massacesi C., Sahmoud T., et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010, 28(34):5110-5115.
92. Jerusalem G., Fasolo A., Dieras V., Cardoso F., Bergh J., Vittori L., et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011, 125(2):447-455.
93. Morrow P.K., Wulf G.M., Ensor J., Booser D.J., Moore J.A., Flores P.R., et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011, 29(23):3126-3132.
94. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008, 68(19):8022-8030.
95. Yen L., You X.L., Al Moustafa A.E., Batist G., Hynes N.E., Mader S., et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000, 19(31):3460-3469.
96. du Manoir J.M., Francia G., Man S., Mossoba M., Medin J.A., Viloria-Petit A., et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006, 12(3 Pt. 1):904-916.
97. Hurvitz SAPM, Lin LS. Final results of a phase 2 trial evaluating trastuzumab and bevacizumab as first-line treatment of HER2-amplified advanced breast cancer. Proc SABCS 2009 [Abstract 6094].
98. Gianni L., Romieu G., Lichinitser M., Serrano S., Mansutti M., Pivot X., et al. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H)+docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Cancer Res 2011, 71(24):S4-S8.
99. Whenham N., D'Hondt V., Piccart M.J. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin Breast Cancer 2008, 8(1):38-49.
100. Nahta R., Hung M.C., Esteva F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004, 64(7):2343-2346.
101. Baselga J., Gelmon K.A., Verma S., Wardley A., Conte P., Miles D., et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010, 28(7):1138-1144.
102. Baselga J., Cortes J., Kim S.B., Im S.A., Hegg R., Im Y.H., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366(2):109-119.
103. Gianni L., Pienkowski T., Im Y.H., Roman L., Tseng L.M., Liu M.C., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13(1):25-32.
104. Krop I.E., Beeram M., Modi S., Jones S.F., Holden S.N., Yu W., et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010, 28(16):2698-2704.
105. Burris H.A., Rugo H.S., Vukelja S.J., Vogel C.L., Borson R.A., Limentani S., et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011, 29(4):398-405.
106. Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. Poster presented at: Annual San Antonio Breast Cancer Symposium, San Antonio, Texas 2009 [Abstract 710].
107. Hurvitz S., Dirix L., Kocsis J., Gianni L., Lu J., Vinholes J., et al. Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H+T) in previously-untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/B021976. Eur J Cancer 2011, 47(S330). [Abstract 5001].
108. Mittendorf E.A., Holmes J.P., Ponniah S., Peoples G.E. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 2008, 57(10):1511-1521.
109. Disis M.L., Wallace D.R., Gooley T.A., Dang Y., Slota M., Lu H., et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009, 27(28):4685-4692.
110. Bodmer M., Meier C., Krahenbuhl S., Jick S.S., Meier C.R. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010, 33(6):1304-1308.
111. Vazquez-Martin A., Oliveras-Ferraros C., Menendez J.A. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2009, 8(1):88-96.
112. Vazquez-Martin A., Oliveras-Ferraros C., Del Barco S., Martin-Castillo B., Menendez J.A. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 2011, 126(2):355-364.
113. Burstein H.J., Sun Y., Dirix L.Y., Jiang Z., Paridaens R., Tan A.R., et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010, 28(8):1301-1307.
114. Hickish T., Wheatley D., Lin N., Carey L., Houston S., Mendelson D., et al. Use of BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. Cancer Res 2009, 69(24s). [Abstract 5060].